25 XP   0   0   10

Immatics NV
Buy, Hold or Sell?

Let's analyse Immatics together

PenkeI guess you are interested in Immatics NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Immatics NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Immatics NV

I send you an email if I find something interesting about Immatics NV.

Quick analysis of Immatics (30 sec.)










What can you expect buying and holding a share of Immatics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.34
Expected worth in 1 year
$2.46
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.12
Return On Investment
1.3%

For what price can you sell your share?

Current Price per Share
$9.78
Expected price per share
$7.98 - $12.47
How sure are you?
50%

1. Valuation of Immatics (5 min.)




Live pricePrice per Share (EOD)

$9.78

Intrinsic Value Per Share

$44.54 - $53.80

Total Value Per Share

$46.87 - $56.14

2. Growth of Immatics (5 min.)




Is Immatics growing?

Current yearPrevious yearGrowGrow %
How rich?$240.8m$148.5m$89.8m37.7%

How much money is Immatics making?

Current yearPrevious yearGrowGrow %
Making money-$24.7m$8.1m-$32.8m-133.1%
Net Profit Margin-218.9%-57.5%--

How much money comes from the company's main activities?

3. Financial Health of Immatics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#216 / 1010

Most Revenue
#257 / 1010

Most Profit
#744 / 1010

Most Efficient
#641 / 1010

What can you expect buying and holding a share of Immatics? (5 min.)

Welcome investor! Immatics's management wants to use your money to grow the business. In return you get a share of Immatics.

What can you expect buying and holding a share of Immatics?

First you should know what it really means to hold a share of Immatics. And how you can make/lose money.

Speculation

The Price per Share of Immatics is $9.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immatics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immatics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.34. Based on the TTM, the Book Value Change Per Share is $0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $0.49 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immatics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.27-2.8%-0.25-2.6%0.101.0%-0.20-2.0%-0.18-1.8%
Usd Book Value Change Per Share-0.24-2.4%0.030.3%0.495.0%0.121.2%0.101.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.24-2.4%0.030.3%0.495.0%0.121.2%0.101.0%
Usd Price Per Share10.53-10.14-8.85-10.65-9.29-
Price to Earnings Ratio-9.69--9.98--10.02-54.85-44.37-
Price-to-Total Gains Ratio-44.72-0.88--89.38--44.68--44.68-
Price to Book Ratio4.50-4.35-6.62--5.79--4.82-
Price-to-Total Gains Ratio-44.72-0.88--89.38--44.68--44.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.78
Number of shares102
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.030.12
Usd Total Gains Per Share0.030.12
Gains per Quarter (102 shares)3.1611.93
Gains per Year (102 shares)12.6347.70
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1013304838
20251609586
3038290143134
4051420191182
5063550239230
6076680286278
7088810334326
80101940382374
901141070429422
1001261200477470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%4.020.00.016.7%4.020.00.016.7%
Book Value Change Per Share2.02.00.050.0%4.07.01.033.3%6.011.03.030.0%6.011.07.025.0%6.011.07.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share2.02.00.050.0%4.07.01.033.3%6.011.03.030.0%6.011.07.025.0%6.011.07.025.0%

Fundamentals of Immatics

About Immatics NV

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial; and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Fundamental data was last updated by Penke on 2024-04-11 11:44:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Immatics NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immatics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Immatics to the Biotechnology industry mean.
  • A Net Profit Margin of -164.2% means that $-1.64 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immatics NV:

  • The MRQ is -164.2%. The company is making a huge loss. -2
  • The TTM is -218.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-164.2%TTM-218.9%+54.7%
TTM-218.9%YOY-57.5%-161.4%
TTM-218.9%5Y-300.7%+81.8%
5Y-300.7%10Y-380.4%+79.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-164.2%-207.2%+43.0%
TTM-218.9%-216.8%-2.1%
YOY-57.5%-282.3%+224.8%
5Y-300.7%-436.8%+136.1%
10Y-380.4%-597.3%+216.9%
1.1.2. Return on Assets

Shows how efficient Immatics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immatics to the Biotechnology industry mean.
  • -5.1% Return on Assets means that Immatics generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immatics NV:

  • The MRQ is -5.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.1%TTM-5.3%+0.2%
TTM-5.3%YOY3.8%-9.1%
TTM-5.3%5Y-11.0%+5.7%
5Y-11.0%10Y-9.2%-1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.1%-13.3%+8.2%
TTM-5.3%-12.8%+7.5%
YOY3.8%-11.6%+15.4%
5Y-11.0%-13.8%+2.8%
10Y-9.2%-15.6%+6.4%
1.1.3. Return on Equity

Shows how efficient Immatics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immatics to the Biotechnology industry mean.
  • -11.6% Return on Equity means Immatics generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immatics NV:

  • The MRQ is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-10.3%-1.3%
TTM-10.3%YOY7.6%-17.9%
TTM-10.3%5Y-20.5%+10.3%
5Y-20.5%10Y-17.1%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-16.9%+5.3%
TTM-10.3%-16.1%+5.8%
YOY7.6%-14.9%+22.5%
5Y-20.5%-19.3%-1.2%
10Y-17.1%-20.1%+3.0%

1.2. Operating Efficiency of Immatics NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immatics is operating .

  • Measures how much profit Immatics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immatics to the Biotechnology industry mean.
  • An Operating Margin of -143.6% means the company generated $-1.44  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immatics NV:

  • The MRQ is -143.6%. The company is operating very inefficient. -2
  • The TTM is -239.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-143.6%TTM-239.8%+96.2%
TTM-239.8%YOY-50.4%-189.4%
TTM-239.8%5Y-198.1%-41.7%
5Y-198.1%10Y-317.2%+119.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-143.6%-298.0%+154.4%
TTM-239.8%-238.5%-1.3%
YOY-50.4%-288.4%+238.0%
5Y-198.1%-486.2%+288.1%
10Y-317.2%-628.4%+311.2%
1.2.2. Operating Ratio

Measures how efficient Immatics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.74 means that the operating costs are $2.74 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immatics NV:

  • The MRQ is 2.741. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.683. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.741TTM4.683-1.942
TTM4.683YOY2.282+2.401
TTM4.6835Y3.143+1.540
5Y3.14310Y0.931+2.212
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7413.235-0.494
TTM4.6833.310+1.373
YOY2.2823.838-1.556
5Y3.1435.679-2.536
10Y0.9317.823-6.892

1.3. Liquidity of Immatics NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immatics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.87 means the company has $2.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immatics NV:

  • The MRQ is 2.870. The company is able to pay all its short-term debts. +1
  • The TTM is 3.103. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.870TTM3.103-0.233
TTM3.103YOY2.892+0.212
TTM3.1035Y2.642+0.462
5Y2.64210Y2.201+0.440
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8703.863-0.993
TTM3.1034.169-1.066
YOY2.8925.337-2.445
5Y2.6426.122-3.480
10Y2.2016.434-4.233
1.3.2. Quick Ratio

Measures if Immatics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immatics to the Biotechnology industry mean.
  • A Quick Ratio of 4.08 means the company can pay off $4.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immatics NV:

  • The MRQ is 4.082. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.851. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.082TTM4.851-0.769
TTM4.851YOY3.848+1.003
TTM4.8515Y3.309+1.543
5Y3.30910Y2.757+0.551
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0823.504+0.578
TTM4.8513.991+0.860
YOY3.8485.371-1.523
5Y3.3096.088-2.779
10Y2.7576.395-3.638

1.4. Solvency of Immatics NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immatics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immatics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.56 means that Immatics assets are financed with 55.9% credit (debt) and the remaining percentage (100% - 55.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immatics NV:

  • The MRQ is 0.559. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.483. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.559TTM0.483+0.076
TTM0.483YOY0.607-0.124
TTM0.4835Y0.795-0.312
5Y0.79510Y0.662+0.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5590.339+0.220
TTM0.4830.337+0.146
YOY0.6070.271+0.336
5Y0.7950.368+0.427
10Y0.6620.388+0.274
1.4.2. Debt to Equity Ratio

Measures if Immatics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immatics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 126.6% means that company has $1.27 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immatics NV:

  • The MRQ is 1.266. The company is able to pay all its debts with equity. +1
  • The TTM is 0.951. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.266TTM0.951+0.315
TTM0.951YOY1.654-0.703
TTM0.9515Y1.446-0.495
5Y1.44610Y1.205+0.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2660.392+0.874
TTM0.9510.403+0.548
YOY1.6540.335+1.319
5Y1.4460.427+1.019
10Y1.2050.461+0.744

2. Market Valuation of Immatics NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Immatics generates.

  • Above 15 is considered overpriced but always compare Immatics to the Biotechnology industry mean.
  • A PE ratio of -9.69 means the investor is paying $-9.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immatics NV:

  • The EOD is -9.001. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.691. Based on the earnings, the company is expensive. -2
  • The TTM is -9.976. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.001MRQ-9.691+0.690
MRQ-9.691TTM-9.976+0.285
TTM-9.976YOY-10.021+0.045
TTM-9.9765Y54.853-64.829
5Y54.85310Y44.373+10.480
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.001-2.300-6.701
MRQ-9.691-2.656-7.035
TTM-9.976-2.718-7.258
YOY-10.021-4.145-5.876
5Y54.853-6.258+61.111
10Y44.373-6.315+50.688
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immatics NV:

  • The EOD is 3.373. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 3.631. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -6.434. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD3.373MRQ3.631-0.259
MRQ3.631TTM-6.434+10.066
TTM-6.434YOY-4.425-2.009
TTM-6.4345Y-12.260+5.826
5Y-12.26010Y-8.269-3.991
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.373-2.974+6.347
MRQ3.631-3.306+6.937
TTM-6.434-3.508-2.926
YOY-4.425-5.613+1.188
5Y-12.260-8.378-3.882
10Y-8.269-8.873+0.604
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immatics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.50 means the investor is paying $4.50 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immatics NV:

  • The EOD is 4.182. Based on the equity, the company is fair priced.
  • The MRQ is 4.503. Based on the equity, the company is fair priced.
  • The TTM is 4.353. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.182MRQ4.503-0.321
MRQ4.503TTM4.353+0.150
TTM4.353YOY6.624-2.271
TTM4.3535Y-5.786+10.139
5Y-5.78610Y-4.822-0.964
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.1821.914+2.268
MRQ4.5032.116+2.387
TTM4.3532.097+2.256
YOY6.6242.881+3.743
5Y-5.7863.550-9.336
10Y-4.8223.936-8.758
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Immatics NV.

3.1. Institutions holding Immatics NV

Institutions are holding 50.557% of the shares of Immatics NV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Wellington Management Company LLP6.16970.0125635292974777213.3408
2023-09-30Baker Bros Advisors LP5.47810.3765564081600
2023-09-30Perceptive Advisors LLC3.39081.3487349150000
2023-12-31Sofinnova Ventures2.88341.74942969039-282470-8.6874
2023-12-31T. Rowe Price Investment Management,Inc.2.74270.0193282416959333326.5969
2023-12-31T. Rowe Price Associates, Inc.2.26680.0033233416971963444.5722
2023-12-31Woodline Partners LP2.01040.23712070083-329917-13.7465
2023-09-30Paradigm Biocapital Advisors LP1.99911.61752058447736343.7099
2023-09-30Nantahala Capital Management, LLC1.86521.89991920636-364259-15.942
2023-12-31Rock Springs Capital Management LP1.82140.4862187546600
2023-12-31Orbimed Advisors, LLC1.49890.3246154340749320746.9631
2023-12-31683 Capital Management LLC1.06830.94871100000200001.8519
2023-09-30Logos Global Management LP1.01971.62221050000550000110
2023-09-30RTW INVESTMENTS, LLC0.82060.206584500000
2023-09-30Hudson Bay Capital Management LP0.77810.0365801160430580116.1908
2023-09-30Alyeska Investment Group, L.P.0.77120.062579406000
2023-12-31HHG PLC0.68410.00447043917043910
2023-09-30University Of Texas Investment Mgmt Co0.67733.577169743100
2023-12-31Artisan Partners Limited Partnership0.66910.0112688950-16264-2.3063
2023-12-31Adage Capital Partners Gp LLC0.60360.013662150029500090.3522
Total 39.218514.557740383153+3634641+9.0%

3.2. Funds holding Immatics NV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Explorer Inv1.73480.088178630000
2024-01-31Wellington Global Hlthcr Eq USD G Ac1.13440.5136116809616799716.798
2023-12-31T. Rowe Price Health Sciences1.01420.0748104429919774723.3591
2023-12-31T. Rowe Price New Horizons0.77290.033979590037090087.2706
2023-12-31US Small-Cap Growth II Equity Comp0.77290.033879590037090087.2706
2023-12-31T. Rowe Price Small-Cap Stock0.71720.0822738523-1100-0.1487
2023-12-31T. Rowe Price US Small-Cap Core Equity0.71720.082738523-1100-0.1487
2023-12-31T. Rowe Price Small-Cap Value0.53250.054654833712310028.9486
2023-11-30Biotech Growth Ord0.50421.255751920000
2023-12-31Artisan International Small-Mid Investor0.42230.102143483400
2023-12-31Artisan Non-U.S. Small-Mid Growth Comp0.42230.10243483400
2023-12-31T. Rowe Price Instl Small-Cap Stock0.3570.08836763800
2023-12-31T. Rowe Price U.S. SC Core Eq Tr-Z0.3420.079535217511000.3133
2023-12-31T. Rowe Price US Smlr Cm Eq A USD0.29980.11563087043204811.5841
2024-02-29BlackRock Health Sciences Opps Inv A0.29010.044129870300
2024-02-29Belfius Equities Cure C Cap0.28650.195429500000
2023-12-31Candriam Global Equities Oncology0.28650.167329500014500096.6667
2024-01-31Hartford Healthcare Y0.25270.25762601552601550
2024-02-29BlackRock Health Sciences Term Trust0.24940.164725677800
2023-12-31T. Rowe Price U.S. SC Value Eq Tr-Z0.23730.05212443095850031.4839
Total 11.34623.58711683208+1725247+14.8%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Immatics NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2350.031-861%0.491-148%0.117-301%0.097-342%
Book Value Per Share--2.3382.314+1%1.442+62%0.929+152%0.774+202%
Current Ratio--2.8703.103-7%2.892-1%2.642+9%2.201+30%
Debt To Asset Ratio--0.5590.483+16%0.607-8%0.795-30%0.662-16%
Debt To Equity Ratio--1.2660.951+33%1.654-23%1.446-12%1.205+5%
Dividend Per Share----0%-0%-0%-0%
Eps---0.272-0.252-7%0.097-379%-0.200-26%-0.180-34%
Free Cash Flow Per Share--0.725-0.033+105%0.016+4311%-0.040+106%-0.025+103%
Free Cash Flow To Equity Per Share--0.7150.186+283%0.304+135%0.167+329%0.158+353%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--53.805--------
Intrinsic Value_10Y_min--44.536--------
Intrinsic Value_1Y_max--0.503--------
Intrinsic Value_1Y_min--0.491--------
Intrinsic Value_3Y_max--5.237--------
Intrinsic Value_3Y_min--4.925--------
Intrinsic Value_5Y_max--14.463--------
Intrinsic Value_5Y_min--13.104--------
Market Cap1007193300.000-8%1084432050.0001044010437.500+4%911674712.500+19%1097253682.500-1%956430277.083+13%
Net Profit Margin---1.642-2.189+33%-0.575-65%-3.007+83%-3.804+132%
Operating Margin---1.436-2.398+67%-0.504-65%-1.981+38%-3.172+121%
Operating Ratio--2.7414.683-41%2.282+20%3.143-13%0.931+194%
Pb Ratio4.182-8%4.5034.353+3%6.624-32%-5.786+228%-4.822+207%
Pe Ratio-9.001+7%-9.691-9.976+3%-10.021+3%54.853-118%44.373-122%
Price Per Share9.780-8%10.53010.138+4%8.853+19%10.655-1%9.287+13%
Price To Free Cash Flow Ratio3.373-8%3.631-6.434+277%-4.425+222%-12.260+438%-8.269+328%
Price To Total Gains Ratio-41.531+7%-44.7160.879-5189%-89.379+100%-44.6780%-44.6780%
Quick Ratio--4.0824.851-16%3.848+6%3.309+23%2.757+48%
Return On Assets---0.051-0.053+3%0.038-234%-0.110+115%-0.092+79%
Return On Equity---0.116-0.103-11%0.076-252%-0.205+77%-0.171+47%
Total Gains Per Share---0.2350.031-861%0.491-148%0.117-301%0.097-342%
Usd Book Value--240817371.600238355531.700+1%148512551.525+62%95662366.881+152%79718639.068+202%
Usd Book Value Change Per Share---0.2350.031-861%0.491-148%0.117-301%0.097-342%
Usd Book Value Per Share--2.3382.314+1%1.442+62%0.929+152%0.774+202%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.272-0.252-7%0.097-379%-0.200-26%-0.180-34%
Usd Free Cash Flow--74661901.600-3404689.275+105%1692581.800+4311%-4156802.228+106%-2564528.010+103%
Usd Free Cash Flow Per Share--0.725-0.033+105%0.016+4311%-0.040+106%-0.025+103%
Usd Free Cash Flow To Equity Per Share--0.7150.186+283%0.304+135%0.167+329%0.158+353%
Usd Market Cap1007193300.000-8%1084432050.0001044010437.500+4%911674712.500+19%1097253682.500-1%956430277.083+13%
Usd Price Per Share9.780-8%10.53010.138+4%8.853+19%10.655-1%9.287+13%
Usd Profit---27975745.200-24706665.750-12%8166011.750-443%-22141299.651-21%-19760551.484-29%
Usd Revenue--17033877.90014442847.575+18%45651295.625-63%16590043.259+3%13993099.507+22%
Usd Total Gains Per Share---0.2350.031-861%0.491-148%0.117-301%0.097-342%
 EOD+4 -4MRQTTM+16 -17YOY+16 -175Y+20 -1310Y+20 -13

4.2. Fundamental Score

Let's check the fundamental score of Immatics NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.001
Price to Book Ratio (EOD)Between0-14.182
Net Profit Margin (MRQ)Greater than0-1.642
Operating Margin (MRQ)Greater than0-1.436
Quick Ratio (MRQ)Greater than14.082
Current Ratio (MRQ)Greater than12.870
Debt to Asset Ratio (MRQ)Less than10.559
Debt to Equity Ratio (MRQ)Less than11.266
Return on Equity (MRQ)Greater than0.15-0.116
Return on Assets (MRQ)Greater than0.05-0.051
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Immatics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.469
Ma 20Greater thanMa 5010.519
Ma 50Greater thanMa 10011.372
Ma 100Greater thanMa 20011.054
OpenGreater thanClose10.010
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets509,965
Total Liabilities284,881
Total Stockholder Equity225,084
 As reported
Total Liabilities 284,881
Total Stockholder Equity+ 225,084
Total Assets = 509,965

Assets

Total Assets509,965
Total Current Assets449,370
Long-term Assets60,595
Total Current Assets
Cash And Cash Equivalents 218,472
Short-term Investments 207,423
Net Receivables 5,737
Inventory 10,619
Other Current Assets 7,119
Total Current Assets  (as reported)449,370
Total Current Assets  (calculated)449,370
+/-0
Long-term Assets
Property Plant Equipment 57,055
Intangible Assets 1,523
Long-term Assets Other 2,017
Long-term Assets  (as reported)60,595
Long-term Assets  (calculated)60,595
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities156,552
Long-term Liabilities128,329
Total Stockholder Equity225,084
Total Current Liabilities
Short-term Debt 2,604
Accounts payable 7,666
Other Current Liabilities 45,881
Total Current Liabilities  (as reported)156,552
Total Current Liabilities  (calculated)56,151
+/- 100,401
Long-term Liabilities
Capital Lease Obligations 15,402
Long-term Liabilities Other 4
Long-term Liabilities  (as reported)128,329
Long-term Liabilities  (calculated)15,406
+/- 112,923
Total Stockholder Equity
Common Stock847
Retained Earnings -597,293
Accumulated Other Comprehensive Income -1,636
Other Stockholders Equity 823,166
Total Stockholder Equity (as reported)225,084
Total Stockholder Equity (calculated)225,084
+/-0
Other
Capital Stock847
Cash and Short Term Investments 425,895
Common Stock Shares Outstanding 84,658
Current Deferred Revenue100,401
Liabilities and Stockholders Equity 509,965
Net Debt -203,070
Net Invested Capital 225,084
Net Working Capital 292,818
Property Plant and Equipment Gross 79,920
Short Long Term Debt Total 15,402



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
0
33,569
33,569
33,569
134,277
63,662
107,933
283,035
254,646
237,772
216,505
198,911
174,646
282,182
354,293
354,293
407,820
378,488
410,189
437,450
509,965
509,965437,450410,189378,488407,820354,293354,293282,182174,646198,911216,505237,772254,646283,035107,93363,662134,27733,56933,56933,5690000
   > Total Current Assets 
0
0
0
0
31,000
31,000
31,000
124,000
59,748
92,087
266,867
238,991
221,996
198,338
180,136
152,207
259,918
322,311
322,311
377,154
345,055
364,625
385,007
449,370
449,370385,007364,625345,055377,154322,311322,311259,918152,207180,136198,338221,996238,991266,86792,08759,748124,00031,00031,00031,0000000
       Cash And Cash Equivalents 
0
0
0
0
25,838
25,838
25,838
103,353
51,883
86,056
233,676
207,530
195,333
160,093
161,294
132,994
247,316
178,047
178,047
148,519
117,919
130,405
83,446
218,472
218,47283,446130,405117,919148,519178,047178,047247,316132,994161,294160,093195,333207,530233,67686,05651,883103,35325,83825,83825,8380000
       Short-term Investments 
0
0
0
0
4,006
4,006
4,006
16,023
6,112
0
25,624
24,448
21,322
32,712
11,920
12,123
5,428
131,287
131,287
213,686
211,894
217,222
282,574
207,423
207,423282,574217,222211,894213,686131,287131,2875,42812,12311,92032,71221,32224,44825,62406,11216,0234,0064,0064,0060000
       Net Receivables 
0
0
0
0
681
681
681
2,723
731
2,286
2,373
2,923
2,174
2,684
3,151
682
2,597
1,992
1,992
1,111
1,186
1,935
1,389
5,737
5,7371,3891,9351,1861,1111,9921,9922,5976823,1512,6842,1742,9232,3732,2867312,7236816816810000
       Other Current Assets 
0
0
0
0
475
475
475
665
1,023
2,351
1,752
787
849
1,019
1,105
6,408
1,073
2,060
2,060
13,838
4,047
5,517
6,777
7,119
7,1196,7775,5174,04713,8382,0602,0601,0736,4081,1051,0198497871,7522,3511,0236654754754750000
   > Long-term Assets 
0
0
0
0
2,569
2,569
2,569
10,277
3,914
15,846
16,168
15,655
15,776
18,167
18,775
22,439
22,264
31,982
31,982
30,666
33,433
45,564
52,443
60,595
60,59552,44345,56433,43330,66631,98231,98222,26422,43918,77518,16715,77615,65516,16815,8463,91410,2772,5692,5692,5690000
       Property Plant Equipment 
0
0
0
0
2,002
2,002
2,002
8,007
3,504
14,162
14,567
14,016
14,267
16,060
16,779
20,488
20,098
26,425
26,425
26,489
29,600
41,937
49,149
57,055
57,05549,14941,93729,60026,48926,42526,42520,09820,48816,77916,06014,26714,01614,56714,1623,5048,0072,0022,0022,0020000
       Intangible Assets 
0
0
0
0
252
252
252
1,008
228
0
0
913
0
0
0
1,315
1,309
0
1,542
1,632
1,565
1,655
0
1,523
1,52301,6551,5651,6321,54201,3091,315000913002281,0082522522520000
       Other Assets 
0
0
0
0
0
0
0
0
1,151
696
632
724
589
845
719
636
879
4,678
4,015
2,545
2,268
1,972
0
0
001,9722,2682,5454,0154,6788796367198455897246326961,15100000000
> Total Liabilities 
0
0
0
0
43,778
43,778
43,778
175,112
37,598
175,924
161,376
150,390
144,085
140,065
163,750
150,583
166,195
241,249
241,249
194,656
178,404
191,976
189,699
284,881
284,881189,699191,976178,404194,656241,249241,249166,195150,583163,750140,065144,085150,390161,376175,92437,598175,11243,77843,77843,7780000
   > Total Current Liabilities 
0
0
0
0
17,324
17,324
17,324
69,296
15,152
87,851
76,190
60,609
68,003
73,128
107,120
95,148
91,854
124,122
124,122
106,452
100,579
124,306
121,148
156,552
156,552121,148124,306100,579106,452124,122124,12291,85495,148107,12073,12868,00360,60976,19087,85115,15269,29617,32417,32417,3240000
       Short-term Debt 
0
0
0
0
0
0
0
1,411
0
1,935
1,939
1,881
1,978
2,321
2,600
2,711
2,770
2,424
2,424
2,159
2,453
2,737
2,789
2,604
2,6042,7892,7372,4532,1592,4242,4242,7702,7112,6002,3211,9781,8811,9391,93501,4110000000
       Accounts payable 
0
0
0
0
1,217
1,217
1,217
4,866
639
8,082
9,743
2,554
10,304
9,407
11,842
11,624
13,304
12,828
12,828
13,056
4,710
5,473
6,155
7,666
7,6666,1555,4734,71013,05612,82812,82813,30411,62411,8429,40710,3042,5549,7438,0826394,8661,2171,2171,2170000
       Other Current Liabilities 
0
0
0
0
1,200
1,200
1,200
3,390
2,864
12,166
3,859
9,574
2,387
3,402
30,801
30,411
14,336
28,720
28,720
26,280
28,646
48,099
50,155
45,881
45,88150,15548,09928,64626,28028,72028,72014,33630,41130,8013,4022,3879,5743,85912,1662,8643,3901,2001,2001,2000000
   > Long-term Liabilities 
0
0
0
0
26,454
26,454
26,454
105,816
22,445
88,073
85,186
89,781
76,082
66,937
56,630
55,435
74,341
117,127
117,127
88,204
77,825
67,670
68,551
128,329
128,32968,55167,67077,82588,204117,127117,12774,34155,43556,63066,93776,08289,78185,18688,07322,445105,81626,45426,45426,4540000
       Other Liabilities 
0
0
0
0
0
0
0
0
92,141
82,534
80,295
85,475
71,707
62,201
52,232
48,293
67,850
115,380
103,270
0
65,312
53,585
0
0
0053,58565,3120103,270115,38067,85048,29352,23262,20171,70785,47580,29582,53492,14100000000
> Total Stockholder Equity
0
0
0
0
-10,209
-10,209
-10,209
-41,855
26,064
-68,499
121,659
104,256
93,687
76,440
35,161
24,063
115,987
113,044
113,044
213,164
200,084
218,213
247,751
225,084
225,084247,751218,213200,084213,164113,044113,044115,98724,06335,16176,44093,687104,256121,659-68,49926,064-41,855-10,209-10,209-10,2090000
   Common Stock
0
0
0
0
291
291
291
1,164
157
1,164
629
629
629
629
629
629
629
657
657
767
767
804
847
847
8478478047677676576576296296296296296296291,1641571,1642912912910000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income -1,636-712-1,141-917-1,481-2,818-2,818-3,385-3,945-4,883-6,135-4,734-7,459-4,157-671-3,642-770-3,178-3,178-3,1780000
   Capital Surplus 
0
0
0
0
3,654
2,797
2,180
1,794
5,064
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000005,0641,7942,1802,7973,6540000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
50,977
50,977
50,977
190,945
145,112
193,551
564,852
573,339
581,643
589,609
560,441
565,192
570,894
602,272
602,272
714,177
720,280
763,206
818,761
823,166
823,166818,761763,206720,280714,177602,272602,272570,894565,192560,441589,609581,643573,339564,852193,551145,112190,94550,97750,97750,9770000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue53,997
Cost of Revenue-0
Gross Profit53,99753,997
 
Operating Income (+$)
Gross Profit53,997
Operating Expense-155,722
Operating Income-101,725-101,725
 
Operating Expense (+$)
Research Development118,663
Selling General Administrative38,198
Selling And Marketing Expenses0
Operating Expense155,722156,861
 
Net Interest Income (+$)
Interest Income13,845
Interest Expense-831
Other Finance Cost-0
Net Interest Income13,014
 
Pretax Income (+$)
Operating Income-101,725
Net Interest Income13,014
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-96,994-93,442
EBIT - interestExpense = -88,711
-96,163
-96,163
Interest Expense831
Earnings Before Interest and Taxes (EBIT)-87,880-96,163
Earnings Before Interest and Taxes (EBITDA)-80,646
 
After tax Income (+$)
Income Before Tax-96,994
Tax Provision-0
Net Income From Continuing Ops-96,994-96,994
Net Income-96,994
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses155,722
Total Other Income/Expenses Net-8,283-13,014
 

Technical Analysis of Immatics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Immatics. The general trend of Immatics is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Immatics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Immatics NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.35 < 11.24 < 12.47.

The bearish price targets are: 9.13 > 8.81 > 7.98.

Tweet this
Immatics NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Immatics NV. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Immatics NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Immatics NV. The current macd is -0.3593584.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Immatics price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Immatics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Immatics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Immatics NV Daily Moving Average Convergence/Divergence (MACD) ChartImmatics NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Immatics NV. The current adx is 25.23.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Immatics shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Immatics NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Immatics NV. The current sar is 11.13.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Immatics NV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Immatics NV. The current rsi is 31.47. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Immatics NV Daily Relative Strength Index (RSI) ChartImmatics NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Immatics NV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Immatics price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Immatics NV Daily Stochastic Oscillator ChartImmatics NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Immatics NV. The current cci is -202.63634074.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Immatics NV Daily Commodity Channel Index (CCI) ChartImmatics NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Immatics NV. The current cmo is -46.19400072.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Immatics NV Daily Chande Momentum Oscillator (CMO) ChartImmatics NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Immatics NV. The current willr is -92.99363057.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Immatics NV Daily Williams %R ChartImmatics NV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Immatics NV.

Immatics NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Immatics NV. The current atr is 0.49447797.

Immatics NV Daily Average True Range (ATR) ChartImmatics NV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Immatics NV. The current obv is 26,277,630.

Immatics NV Daily On-Balance Volume (OBV) ChartImmatics NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Immatics NV. The current mfi is 35.59.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Immatics NV Daily Money Flow Index (MFI) ChartImmatics NV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Immatics NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Immatics NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Immatics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.469
Ma 20Greater thanMa 5010.519
Ma 50Greater thanMa 10011.372
Ma 100Greater thanMa 20011.054
OpenGreater thanClose10.010
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Immatics with someone you think should read this too:
  • Are you bullish or bearish on Immatics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Immatics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Immatics NV

I send you an email if I find something interesting about Immatics NV.


Comments

How you think about this?

Leave a comment

Stay informed about Immatics NV.

Receive notifications about Immatics NV in your mailbox!